Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

precision oncology

Roche's Perjeta pertuzumab

NICE backs Roche’s Perjeta for routine NHS use

Set to become first new breast cancer drug in nine years after discount agreed

EU flag

Pfizer’s first-in-class breast cancer therapy wins EU licence

Ibrance given the green light as a first-line treatment in Europe

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

NICE backs Eisai’s Halaven for breast cancer

Reverses 2012 rejection due to new data and patient access discount

- PMLiVE

Man Boobs campaign wins at D&AD Impact Awards

Takes home White Pencil in inaugural awards for creative contribution to society

Eli Lilly HQ

Lilly presses on with breast cancer study despite setback

CDK 4/6 inhibitor abemaciclib shows disappointing results in phase III trial

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

Eli Lilly HQ

Lilly and Boehringer combine breast cancer drugs in trial

Firms anticipate together the two drugs will offer a “more complete pathway interference”

- PMLiVE

Trial backs Keytruda use first-line in lung cancer

Suggests Merck & Co’s drug is more effective than chemotherapy for NSCLC patients

- PMLiVE

Biosimilar trastuzumab comparable to brand, ASCO hears

Roche’s Herceptin matched in safety and efficacy by Mylan and Biocon’s breast cancer drug

Novartis building

Novartis says Cosentyx is ‘outpacing competitors’

Claims new psoriasis drug has almost a third of the market share in Germany alone

Roche's Perjeta pertuzumab

NICE rejects Roche’s breast cancer drug Perjeta

Says the treatment's long-term benefits are unclear

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links